Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Letter from Robert Farrell. Summary:

<< Previous

Bullboard Posts

Next >>

Post by deanthebeanon May 25, 2020 7:32am

203 Views

Post# 31067851

Letter from Robert Farrell. Summary:

- they are going in heavy with the covid-19 treatment
- actively pursuing a sale of the GVHD
- kal-1816 pain relief; they are advancing the program through phase 1 and 2
- announced private placement expected closing date

so in summary we are currently a covid play it seems. Let's hope there is real substance to it and it's not just being pushed to the forefront in order to give excitement to the private placement!

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects